iBio Revenue and Competitors

At iBio, we’re enabling the next generation of biologics with the FastPharming® System for high-quality, eco-friendly recombinant protein production. A wide array of proteins can be efficiently expressed using our Nicotiana benthamiana plants, and readily scaled-up for high-volume production in our 130,000-square-foot FastPharming Facility in Bryan, Texas. We’re putting these capabilities to work for our clients via an array of contract development and manufacturing services, as well as deploying them for the advancement our own pipeline of therapeutics, vaccines, and products for research & bioprocessing applications. Plus, with our new Glycaneering™ Development Service, we have greater control over protein glycoforms, including the ability to remove fucose to create more potent monoclonal antibody therapeutics. Our innovative, hard-working teams are combining our technologies and capabilities to address unmet medical needs in human health and veterinary medicine, while enabling our clients to advance their biopharmaceuticals and 3D-bioprinted/tissue-engineered products through the clinic and to market.